Crossmark Global Holdings Inc. Sells 15,987 Shares of CVS Health Corporation $CVS

Crossmark Global Holdings Inc. reduced its holdings in CVS Health Corporation (NYSE:CVS) by 4.2% during the fourth quarter, Holdings Channel.com reports. The fund owned 368,561 shares of the pharmacy operator’s stock after selling 15,987 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in CVS Health were worth $29,249,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of CVS. Caitong International Asset Management Co. Ltd raised its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after purchasing an additional 281 shares in the last quarter. Corundum Trust Company INC bought a new position in shares of CVS Health during the third quarter valued at about $29,000. Ares Financial Consulting LLC bought a new stake in CVS Health in the fourth quarter valued at approximately $29,000. GoalVest Advisory LLC bought a new stake in CVS Health in the 4th quarter worth $32,000. Finally, Financial Consulate Inc. increased its holdings in CVS Health by 99.6% during the 4th quarter. Financial Consulate Inc. now owns 499 shares of the pharmacy operator’s stock valued at $40,000 after purchasing an additional 249 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS beat Wall Street expectations on Q1 earnings and revenue, reporting about $2.9 billion in profit, with improved Aetna profitability helping drive the upside. The company also raised its 2026 outlook, which investors are reading as a sign that the turnaround is gaining traction. CVS Raises 2026 Outlook As Shares Jump 9.8%
• Positive Sentiment: Several brokerages lifted price targets on CVS, including UBS to $100, Truist to $102, and Deutsche Bank to $92, reinforcing the view that recent operating improvements could support more upside from here.
• Positive Sentiment: Analysts and media reports highlighted improving Medicare Advantage metrics, better medical benefit ratios, and operational efficiencies, suggesting CVS’s health insurance business is moving back toward its longer-term margin targets.
• Positive Sentiment: Commentary from investors and media noted that CVS’s prescription volume and pharmacy operations remain solid, while biosimilar and AI initiatives may support long-term cost control and affordability efforts.
• Neutral Sentiment: Pieces discussing Jim Cramer’s prior favorable view on CVS and articles questioning whether the stock is still attractive mainly reinforce sentiment around the name, but do not add new fundamental information.
• Negative Sentiment: Some articles pointed to ongoing structural pressure in the PBM business and the risk that temporary insurance profit strength may not fully offset longer-term margin challenges.

CVS Health Trading Up 3.6%

CVS Health stock opened at $90.50 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $90.89. The firm has a market capitalization of $115.47 billion, a price-to-earnings ratio of 39.87, a P/E/G ratio of 0.88 and a beta of 0.60. The firm has a 50 day moving average of $76.86 and a 200 day moving average of $78.03.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. During the same period in the prior year, the company posted $2.25 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, research analysts predict that CVS Health Corporation will post 7.43 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health’s dividend payout ratio (DPR) is currently 192.75%.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of research reports. Robert W. Baird lifted their target price on shares of CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. HSBC raised their price objective on shares of CVS Health from $83.00 to $85.00 and gave the company a “hold” rating in a research note on Tuesday. Truist Financial increased their price objective on CVS Health from $98.00 to $102.00 and gave the company a “buy” rating in a research report on Thursday. Bank of America cut their target price on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Finally, Piper Sandler cut their price objective on CVS Health from $101.00 to $99.00 and set an “overweight” rating for the company in a report on Tuesday, March 31st. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $95.92.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.